It is interesting to consider these results in the context of two recent studies where the combinatorial effect of Palbociclib and MEK inhibitor (Trametinib) was tested in models of KRAS-driven NKX2-1-positive LUAD (Ruscetti et al., 2018) and in KRAS-driven pancreatic ductal adenocarcinoma (PDAC) (Ruscetti et al., 2020). This evidence concerns the gene NKX2-1 and pancreatic ductal adenocarcinoma.